Veracyte (VCYT) CMO Phillip Febbo Sells 13,110 Shares

What Happened

• Phillip G. Febbo, Veracyte's Chief Scientific & Medical Officer, disposed of 13,110 shares in open-market sales on September 4, 2026. The two sales were for 10,405 shares at a weighted average price of about $42.89 ($446,305) and 2,705 shares at a weighted average price of about $43.66 ($118,105), totaling roughly $564,410.
• Separately, 3,639 shares were withheld on September 2, 2026 to satisfy tax withholding related to the vesting of restricted stock units (valued at $163,318); the filing clarifies those withheld shares do not represent a sale.

Key Details

• Transaction dates: Sep 2, 2026 (tax withholding on RSUs); Sep 4, 2026 (open-market sales).
• Reported sales: 10,405 shares ($446,305) and 2,705 shares ($118,105); total open-market proceeds ≈ $564,410.
• Tax withholding: 3,639 shares withheld to cover taxes on RSU vesting (value ≈ $163,318) — not a sale.
• Price range per footnotes: sales prices ranged from $42.47 to $44.16 (weighted averages reported; detailed per-price breakdown available upon request).
• Plan/authorization: Open-market transactions were made under a Rule 10b5-1 trading plan adopted Aug 21, 2025.
• Shares owned after transaction: not specified in the provided Form 4 excerpt.
• Filing: Form 4 was filed Sep 4, 2026; the report appears to be filed within the standard reporting window.

Context

• The sales were executed under a pre-established 10b5-1 plan, which is a routine mechanism insiders use to sell shares on a set schedule and does not by itself indicate a change in intent or sentiment.
• The withheld shares reflect tax settlement of vested RSUs (a common administrative step) rather than an active sale decision.
• For retail investors: purchases generally carry more informational weight than routine sales; these transactions appear consistent with planned sales and RSU tax withholding rather than ad hoc insider selling.